These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36630072)

  • 1. Belzutifan (MK-6482): Biology and Clinical Development in Solid Tumors.
    Choi WW; Boland JL; Kalola A; Lin J
    Curr Oncol Rep; 2023 Feb; 25(2):123-129. PubMed ID: 36630072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Belzutifan: a novel therapeutic for the management of von Hippel-Lindau disease and beyond.
    Curry L; Soleimani M
    Future Oncol; 2024; 20(18):1251-1266. PubMed ID: 38639572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Belzutifan, HIF-2α Inhibitor, and Clear Cell Renal Cell Carcinoma With Somatic Von-Hippel-Lindau Loss-of-Function Mutation.
    Chan KH; Li N; Lador R; Amsbaugh M; Gonzalez A; Cen P
    J Investig Med High Impact Case Rep; 2024; 12():23247096241231641. PubMed ID: 38344974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis.
    Choueiri TK; Bauer TM; Papadopoulos KP; Plimack ER; Merchan JR; McDermott DF; Michaelson MD; Appleman LJ; Thamake S; Perini RF; Zojwalla NJ; Jonasch E
    Nat Med; 2021 May; 27(5):802-805. PubMed ID: 33888901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.
    Jonasch E; Donskov F; Iliopoulos O; Rathmell WK; Narayan VK; Maughan BL; Oudard S; Else T; Maranchie JK; Welsh SJ; Thamake S; Park EK; Perini RF; Linehan WM; Srinivasan R;
    N Engl J Med; 2021 Nov; 385(22):2036-2046. PubMed ID: 34818478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Belzutifan: A Narrative Drug Review.
    Visweswaran V; Pavithran K
    Curr Drug Res Rev; 2022; 14(2):88-95. PubMed ID: 35366789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Belzutifan in a Patient With VHL-Associated Metastatic Pancreatic Neuroendocrine Tumor.
    Pelle E; Al-Toubah T; Morse B; Strosberg J
    J Natl Compr Canc Netw; 2022 Dec; 20(12):1285-1287. PubMed ID: 36509068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The road to systemic therapy in von Hippel-Lindau (VHL) disease: Are we there yet?
    Shepherd STC; Drake WM; Turajlic S
    Eur J Cancer; 2023 Mar; 182():15-22. PubMed ID: 36708612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting HIF-2α and anemia: A therapeutic breakthrough for clear-cell renal cell carcinoma.
    Rioja P; Rey-Cardenas M; De Velasco G
    Cancer Treat Rev; 2024 Sep; 129():102801. PubMed ID: 39032449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurological applications of belzutifan in von Hippel-Lindau disease.
    Zhang Y; Nguyen CC; Zhang NT; Fink NS; John JD; Venkatesh OG; Roe JD; Hoffman SC; Lesniak MS; Wolinsky JP; Horbinski C; Szymaniak BM; Buerki RA; Sosman JA; Shenoy NK; Lukas RV
    Neuro Oncol; 2023 May; 25(5):827-838. PubMed ID: 36215167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurosurgical Implications of Targeting Hypoxia-Inducible Factor 2α in Hemangioblastomas with Belzutifan.
    Pumford AD; Bauman M; Bouchal S; Riviere-Cazaux C; Jusue-Torres I; Hong S; Neth BJ; Sener U; Parney IF
    World Neurosurg; 2024 Oct; 190():291-296. PubMed ID: 39094939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].
    Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ
    Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study.
    Iliopoulos O; Iversen AB; Narayan V; Maughan BL; Beckermann KE; Oudard S; Else T; Maranchie JK; Goldberg CM; Fu W; Perini RF; Liu Y; Linehan WM; Srinivasan R; Jonasch E
    Lancet Oncol; 2024 Oct; 25(10):1325-1336. PubMed ID: 39284337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Belzutifan: First Approval.
    Deeks ED
    Drugs; 2021 Nov; 81(16):1921-1927. PubMed ID: 34613603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma.
    Hasanov E; Jonasch E
    Expert Opin Investig Drugs; 2021 May; 30(5):495-504. PubMed ID: 33945366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort.
    Jonasch E; Bauer TM; Papadopoulos KP; Plimack ER; Merchan JR; McDermott DF; Dror Michaelson M; Appleman LJ; Roy A; Perini RF; Liu Y; Choueiri TK
    Eur J Cancer; 2024 Jan; 196():113434. PubMed ID: 38008031
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Ren X; Diao X; Zhuang J; Wu D
    Mol Pharmacol; 2022 Sep; ():. PubMed ID: 36167425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species.
    Nicholson HE; Tariq Z; Housden BE; Jennings RB; Stransky LA; Perrimon N; Signoretti S; Kaelin WG
    Sci Signal; 2019 Oct; 12(601):. PubMed ID: 31575731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity of
    Stransky LA; Vigeant SM; Huang B; West D; Denize T; Walton E; Signoretti S; Kaelin WG
    Proc Natl Acad Sci U S A; 2022 Apr; 119(14):e2120403119. PubMed ID: 35357972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.